Skip to Content
  • Annual report 2022
    • Management review 2022
    • Small country, big agency
    • Fimea active in EU-level development work
    • A year of many legislative changes for Fimea and operators
    • Fimea has a strong role in pharmaceutical reform
    • Fimea continued to promote medication safety and safe pharmacotherapy
    • Drug advice provided in remote pharmacy services should be improved
    • A Finnish study: Safeguarding efficient antibacterial therapy calls for quick measures
    • Fimea develops services starting from the medical device operator and device register
    • Fimea’s customer satisfaction improved
    • Regulation of veterinary medicines also safeguards human health
    • Personnel training emphasises the sense of community
    • Fimea’s premises in Kuopio moved to Lake Kallavesi
  • Annual report 2021
    • Fimea’s Year 2021
      • COVID-19 continued to generate work
      • Enabling joint discussion and good interaction are important lessons learned for the period 2022-2023
    • Economy 2021
      • Structure of Fimea's funding 2021
    • Statistics 2021
      • Shortage notifications 2016–2021
      • Inspections by control area 2017–2021
      • Marketing authorisation services in 2021
      • Number of marketing authorisations (marketing authorisations valid) 2017–2021
    • Pharmaceutical information 2021
      • Examination of the medicines data repository continued
      • Getting to know the Safe Pharmacotherapy Guide that promotes medication safety
    • Responsibility 2021
      • Responsibility at Fimea – Responsibility report 2021
        • Sustainable well-being through safe and effective medicines and medicinal products
        • Sustainable well-being and economy through rational use of medicines
        • Functional distribution of medicines
        • Impactful supervision
    • Fimea in brief 2021
      • Fimea’s strategy journey continued with the restructuring of its organisation
      • Meds75+ promotes medication safety in older people - the goal is international recognition
  • Annual report 2022
  • Annual report 2021
    • Fimea’s Year 2021
    • Economy 2021
    • Statistics 2021
    • Pharmaceutical information 2021
    • Responsibility 2021
    • Fimea in brief 2021
  • Valitse kieli Suomi
  • Välj språket Svenska
  • Select language English

  • Management review

  • COVID-19 continued to generate work

  • Enabling joint discussion and good interaction are important lessons learned for the period 2022-2023

  • Examination of the medicines data repository continued

    The aim of the overall examination of the medicines data repository is to improve the availability and accessibility of high-quality information that meets the needs of user.

  • Getting to know the Safe Pharmacotherapy Guide that promotes medication safety

    The aim has to been to promote medication safety.

P.O. Box 55, 00034 FIMEA FI

029 522 3341

[email protected]

© Fimea 2023

Fimea promotes the health and safety of the population by regulating medicinal, medical devices, blood and tissue products, biobanks and by developing the pharmaceuticals sector.

Information about this website

  • Data protection (in Finnish)
  • Cookie policies
  • Accessibility statement
false